Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05653973 · ClinicalTrials.gov registry record · Early Phase 1
Prenatal Aspirin and Postpartum Vascular Function
A Early Phase 1 study of Preeclampsia and Microvascular Function, sponsored by Anna Stanhewicz, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05653973 is a Early Phase 1 study of Preeclampsia and Microvascular Function that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 60 participants, below the 1,280-participant average among 39 other Preeclampsia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05653973, a Early Phase 1 study of Preeclampsia and Microvascular Function, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Preeclampsia is a pregnancy disorder affecting \~5-10% of pregnancies in the United States. Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. Low dose aspirin (LDA; 75-150mg/daily) is currently the most effective and clinically accepted therapy for reducing preeclampsia prevalence in women at high risk for developing the syndrome. The purpose of this study is to interrogate the mechanisms by which LDA therapy mitigates persistent vascular dysfunction in postpartum women who have had preeclampsia. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) they examine the blood vessels in a dime-sized area of the skin in women who have had a history of preeclampsia. As a compliment to these measurements, they also draw blood from the subjects and isolate the inflammatory cells.
Conditions Studied
Interventions
- DRUG Acetylcholine
- DRUG Endothelin-1
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-01-03 |
| Est. Completion | 2027-07-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05653973
The ClinicalTrials.gov registry entry for NCT05653973 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,280-participant average among 39 other Preeclampsia trials with a reported enrollment target (95% lower). The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Acetylcholine is the first listed.
NCT05653973 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT05653973 about?
NCT05653973 is a clinical study titled "Prenatal Aspirin and Postpartum Vascular Function". Preeclampsia is a pregnancy disorder affecting \~5-10% of pregnancies in the United States. Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be...
What is the current status of trial NCT05653973?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2023-01-03. Estimated completion is 2027-07-30.
What conditions does trial NCT05653973 study?
This clinical trial studies the following conditions: Preeclampsia, Microvascular Function.
What interventions are being tested in trial NCT05653973?
The interventions under investigation include: Acetylcholine (DRUG), Endothelin-1 (DRUG).
Who is sponsoring clinical trial NCT05653973?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05653973 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Predictors of Aspirin Failure in Preeclampsia Prevention
RECRUITING · Early Phase 1
-
Vascular Effects of High-Salt After Preeclampsia
RECRUITING · Early Phase 1
-
MR and Inflammation After Preeclampsia
ACTIVE NOT RECRUITING · Early Phase 1
-
Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)
COMPLETED · Early Phase 1
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.